Wearable sensors might soon provide dermatologists and patients with unprecedented real-time information about skin health.
One such device in development, Epicore Biosystems’ wearable Discovery patch (Leo Pharma and Epicore Biosystems), aims to assess inflammatory biomarkers found in sweat and interstitial fluid in individuals with atopic dermatitis. The wearable technology will analyze cytokines in sweat to offer realtime objective assessment of the state of disease in adults with the chronic skin condition.
Leo Pharma’s innovation unit Leo Science and Tech Hub announced in early November 2019 that Northwestern University Feinberg School of Medicine Department of Dermatology researchers are starting a phase 2 proof-of-principle study using the patch on adult atopic dermatitis patients to track inflammatory biomarkers on different skin locations.
Northwestern dermatologists completed a study in 2019 testing the clinical utility of the Discovery platform showing the wearable technology quantified target cytokine concentrations in sweat in different skin locations. Steve Xu, M.D., assistant professor of Dermatology at Northwestern and an advisor to Epicore, says sweat is the next frontier for biomarker discovery — one that will open new avenues for early intervention and precision therapy.
“Epicore is an exciting company because it’s really leveraging wearable devices for a biofluid that we’ve long ignored. Sweat offers a rich source of information that Epicore can collect noninvasively,” Dr. Xu says.